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Abstract
The primary aim of precision medicine is to tailor healthcare more closely to the needs of individual patients. This
requires progress in two areas: the development of more precise treatments and the ability to identify patients or
groups of patients in the clinic for whom such treatments are likely to be the most effective. There is widespread
optimism that advances in genomics will facilitate both of these endeavors. It can be argued that of all medical
specialties psychiatry has most to gain in these respects, given its current reliance on syndromic diagnoses, the
minimal foundation of existing mechanistic knowledge, and the substantial heritability of psychiatric phenotypes.
Here, we review recent advances in psychiatric genomics and assess the likely impact of these findings on attempts
to develop precision psychiatry. Emerging findings indicate a high degree of polygenicity and that genetic risk
maps poorly onto the diagnostic categories used in the clinic. The highly polygenic and pleiotropic nature of
psychiatric genetics will impact attempts to use genomic data for prediction and risk stratification, and also poses
substantial challenges for conventional approaches to gaining biological insights from genetic findings. While there
are many challenges to overcome, genomics is building an empirical platform upon which psychiatry can now
progress towards better understanding of disease mechanisms, better treatments, and better ways of targeting
treatments to the patients most likely to benefit, thus paving the way for precision psychiatry.
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Background
The past decade has seen extensive advances in psychi-
atric genomics in disorders such as schizophrenia, bipo-
lar disorder (BD), major depressive disorder (MDD),
autism spectrum disorder (ASD), attention-deficit hyper-
activity disorder (ADHD), intellectual disability (ID), and
anorexia nervosa (Table 1). Recent genetic studies of
psychiatric disorders have generally adopted one of the
following genome-wide approaches: (1) genome-wide as-
sociation studies (GWAS), which compare the
frequencies of single-nucleotide polymorphisms (SNPs)
between cases and controls. GWAS do not usually iden-
tify causal mutations, but instead identify SNPs in high
linkage disequilibrium with the risk variant, thus
highlighting genomic regions containing common risk
alleles. The aggregated risk from common alleles across
the genome is often summarized as per-individual gen-
omic risk scores (GRSs; also known as polygenic risk
scores (PRS)). (2) Rare copy number variant (CNV) stud-
ies, which identify sub-microscopic deletions and dupli-
cations of DNA associated with traits or diseases. (3)
Next-generation sequencing (NGS) studies, which also
allow discovery of other rare variants such as rare single-
nucleotide variants (SNVs) and small insertions/dele-
tions (indels). In psychiatry, most NGS studies to date
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have focused on sequencing the protein-coding regions
of the genome, known as exome sequencing, to identify
specific genes or sets of genes enriched for rare variants.
The findings that have emerged from these studies
have established the genetic architecture of psychiatric
disorders as highly polygenic; hundreds to thousands of
risk alleles are spread widely across the genome. The
population frequencies of these alleles, in part, reflect
the degree to which they increase the risk for developing
a psychiatric disorder; high-risk variants have lower al-
lele frequencies as they are quickly removed from the
population by natural selection [1, 2]. Genetic studies of
psychiatric disorders have also shown that pleiotropy
(i.e., variants associated with multiple traits) is wide-
spread among risk alleles. However, psychiatric disorders
are multifactorial, with environmental exposures also
contributing to their development, such as obstetric
complications, early-life adversities, migration, and sub-
stance abuse [3].
In this review, we will address the question of how re-
cent and future genomic discoveries might be used to
help us to better understand disease mechanisms in
order to develop new treatments and to target current
and future treatments to the patients most likely to
benefit, thus paving the way for precision psychiatry. We
begin by reviewing recent studies that have enhanced
our understanding of the genetic architecture of psychi-
atric disorders, as well as those that have provided in-
sights into their pathophysiology. We then discuss how
the complex genetics of psychiatric disorders have im-
pacted progress in precision psychiatry. Finally, we con-
sider the research agenda for translating recent findings
in psychiatric genetics towards the development of bet-
ter treatments.
Recent advances in neuropsychiatric genomics
Progress has been greater in some disorders than in
others, and we are nowhere near the end of the gene dis-
covery road for any disorder. Nonetheless, enough has
been revealed to delineate two features of the genetics of
these conditions that will have important implications
for translation. First, psychiatric disorders are highly
polygenic, meaning that individual risk reflects the com-
bined effects of variation at many different genetic loci.
Second, there is extensive pleiotropy, with the effects of
risk alleles crossing boundaries between diagnostic cat-
egories and between those disorders and behavioral
traits in non-clinical populations.
Polygenicity
Psychiatric disorders are highly polygenic [Table 2 and
Fig. 1a]. Many common alleles of small effect contribute
to all the major psychiatric disorders studied to date [7,
10, 13, 16, 27, 28], even developmental disorders (DD)
where rare high-penetrance mutations are frequently in-
volved [23, 24]. GWAS have identified hundreds of asso-
ciations between specific SNPs and psychiatric disorders
(Table 2), the majority of which reside in non-coding re-
gions [29, 30]. The greatest progress has been in studies
of schizophrenia, where 145 independent loci are impli-
cated in the most recent published GWAS study of 40,
675 cases and 64,643 controls [4]. With larger samples,
similar progress is likely to be made in other disorders,
such as BD and ADHD, given they have similar esti-
mates of SNP-based heritability to schizophrenia
(Table 2).
Data from genomic microarray and exome sequencing
studies have also implicated rare, more highly penetrant
mutations [6, 14, 15, 24, 31–34]. The strongest evidence
for specific rare variants currently comes from studies of
CNVs, where several pathogenic deletions and duplica-
tions have been identified [6, 15, 25, 32]. These CNVs
are usually large (e.g., disrupting > 500 kb of DNA) and
disrupt multiple genes. Only one single-gene CNV, dele-
tions at NRXN1, has been robustly associated with
schizophrenia [6, 32, 35].
Rare SNVs or indels (hereafter referred to as rare cod-
ing variants (RCVs)), and particularly but not exclusively
loss-of-function variants in highly conserved genes [36],
are enriched in neurodevelopmental disorders (NDDs)
such as ID, ASD, ADHD, and schizophrenia. The burden
of these mutations is greater in more severe, early-onset
disorders such as ID and ASD [37], and there is evidence
that stratification exists according to the presence or ab-
sence of comorbid ID, with pathogenic CNVs and dam-
aging RCVs being more common in cases with cognitive
impairment [38]. To date, RCVs have been associated
with 102 and 94 genes in ASD [14] and DD [24], re-
spectively. The majority of these genes are associated
with LoF variants, with only four genes (SLC6A1,
DEAF1, KCNQ3, and SCN1A) preferentially associated
with missense variants in ASD [14]. In sequencing stud-
ies of schizophrenia, three genes (SETD1A, RBM12, and
SLC6A1) have been robustly associated with RCVs [5,
39, 40]; however, the strong excess of LoF variants in
constrained genes in schizophrenia suggests that add-
itional single-gene associations will emerge from larger
NGS studies.
Finally, there is strong evidence emerging that, in cases
carrying rare high-penetrance risk alleles, outcomes are
to some extent dependent on the burden of common
risk alleles [23, 41–44]. Individuals with schizophrenia
that carry pathogenic CNVs still have an elevated bur-
den of common risk alleles compared with controls [42];
the burden of common risk alleles in CNV carrying
cases is negatively correlated with the effect size of the
CNV (i.e., fewer common risk alleles are found in car-
riers of higher penetrant CNVs) [44]. Schizophrenia
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Fig. 1 a Genetic associations with schizophrenia, bipolar disorder, major depressive disorder, and autism spectrum disorder. Odds ratios (y-axis,
−log10, transformed to be > 1) and minor allele frequencies (MAF, x-axis, −log10, transformed to be ≤ 0.5) for single-nucleotide polymorphisms
(SNPs), rare coding variants (RCVs), and rare copy number variants (CNVs), which were derived from the studies outlined in Table 2. We note that
for ASD, as odds ratios have not been estimated for all classes of mutation, we have plotted the smoothed relative risk for RCVs (as reported in
[14]) and odds ratios for CNVs and SNPs on the same scale, labeled as “Effect sizes,” for illustrative purposes. There is a general trend for a
negative correlation between odds ratio and MAF, which reflects the degree to which selection removes risk alleles from the population. b
Polygenic liability threshold model. For polygenic neuropsychiatric disorders, diverse classes of mutation contribute to liability, with additive
models currently providing the best fit to the data [26]
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patients carrying de novo LoF variants in evolutionary
constrained genes also have a lower burden of common
risk alleles when compared with non-carrying cases [39].
These observations support a liability threshold model of
schizophrenia [26], where fewer common risk alleles are
required to develop schizophrenia in carriers of rare,
more highly penetrant mutations (Fig. 1b).
Pleiotropy
The occurrence of pleiotropy for common risk alleles
has recently been evaluated in an analysis of publicly
available GWAS results from 558 traits, where over 90%
of genome-wide significant loci were shown to be pleio-
tropic [45]. For psychiatric disorders, there is substantial
overlap in rare and common risk alleles in a way that
points to extensive biological pleiotropy [46]. Thus, the
CNVs that are associated with increased risk of schizo-
phrenia are also often associated with ASD, ID and
ADHD [47], and every CNV that confers risk of schizo-
phrenia also does so for ID [48]. Moreover, there is over-
lap between the genes disrupted by de novo RCVs in
schizophrenia, ASD and DD [31, 39, 49]. There is also
extensive pleiotropy of common allele effects as evi-
denced by the substantial genetic correlations observed
between pairs of psychiatric phenotypes [46, 50] and
with a number of behavioral traits [50]. For example,
schizophrenia common alleles are significantly corre-
lated with BD, ADHD, anorexia nervosa, MDD, and
OCD [50]. This degree of pleiotropy is in contrast to the
situation across neurological disorders, where no signifi-
cant correlations have yet been found, although genetic
correlations have been observed between neurological
and psychiatric phenotypes (e.g. migraine is correlated
with Tourette syndrome and MDD) [50]. A recent
cross-disorder meta-analysis of eight psychiatric disor-
ders (schizophrenia, AN, ADHD, ASD,BD, MDD,
obsessive-compulsive disorder and Tourette syndrome)
found 109 genome-wide significant pleiotropic loci af-
fecting more than one disorder, of which 23 loci were
associated with four or more disorders [51]. These ob-
servations almost certainly reflect at least in part the
syndromic nature of psychiatric diagnoses [52] and sup-
port evidence from a variety of sources that current
diagnostic categories are not capturing biologically dis-
tinct disease entities [52].
Biological insights
Studies of rare variants have provided replicated evi-
dence for the involvement of synaptic dysfunction in
schizophrenia pathogenesis [31, 33, 53]. For example,
the activity-regulated cytoskeleton-associated protein
(ARC) and N-methyl-D-aspartate receptor (NMDAR)
postsynaptic protein complexes, which are involved in
synaptic plasticity, are disrupted by de novo CNVs in
schizophrenia [53]. These synaptic genes have also been
associated with schizophrenia in de novo and case-
control RCV studies [31, 33, 54]. However, an excess of
RCVs in schizophrenia exists more broadly across thou-
sands of neuronally expressed genes, in particular those
that are related to the synapse [33]. Common allele stud-
ies of schizophrenia have also implicated genes involved
in calcium signaling and glutamatergic neurotransmis-
sion [29], the latter showing convergence with rare vari-
ant studies in supporting a role for synaptic plasticity.
Genes that regulate transcriptional activity have been
strongly associated with RCVs in several psychiatric dis-
orders; for example, CHD8 and SETD1A, which are in-
volved in chromatin remodeling, are associated with LoF
variants in early-onset NDDs (ASD and DD) and schizo-
phrenia, respectively [5, 14, 24]. Moreover, leukocyte
transcriptomic data from children with ASD and con-
trols has shown genes differentially expressed in ASD
are directly targeted by transcriptional regulators impli-
cated in ASD (e.g. CHD8 and FMR1), and are indirectly
targeted by rare ASD risk alleles that perturb signaling
pathways, such as the RAS–ERK, PI3K–AKT and
WNT–β-catenin pathways [55]. Transcriptomic data
have also highlighted the spatiotemporal expression pat-
terns of ASD risk genes; risk genes involved in regulating
gene activity are preferentially expressed in early fetal
development, whereas risk genes involved in neuronal
communication are most highly expressed in late fetal
and perinatal development [14].
The large number of loci, genes and gene sets that
continue to emerge from studies of psychiatric disorders
makes it challenging to derive specific biological insights
from genetic associations. However, single-cell RNA se-
quencing studies have started to identify cells and tissues
mapping to loci implicated from genetic studies. For ex-
ample, single-nuclei RNA sequencing of cortical tissue
from post-mortem brains found genes to be differentially
expressed within upper-layer cortical neurons and
microglia in ASD [56]. Single-cell RNA sequencing has
also been used to map schizophrenia common risk al-
leles to genes preferentially expressed in pyramidal cells,
medium spiny neurons and interneurons [57].
Implications of genomic findings for progress
towards precision psychiatry
The primary aim of precision medicine is to tailor
healthcare to individual patients (Fig. 2). This will re-
quire progress on two broad fronts. First, we need to be
able to define patients or, more realistically, groups of
patients for whom a particular treatment or other inter-
vention is warranted. Second, we need to develop and
test novel treatments and interventions that can be ap-
plied with a degree of specificity to individual patients or
groups of patients. Indeed, a major justification for the
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pursuit of psychiatric genomics is that it offers a poten-
tially unbiased route into understanding pathogenesis,
and, as a consequence, the promise of new, rationally de-
signed and targeted treatments. The emerging findings
from psychiatric genomics have implications for both of
these and we will consider them in turn.
Clinical stratification
The extensive polygenicity and pleiotropy, which seem
to be the rule rather than the exception in psychiatric
disorders, have important implications for future at-
tempts to use genomic testing in precision psychiatry to
define patients or groups of patients for clinical purposes
[58, 59]. For example, first, not all individuals with a
particular psychiatric disorder will carry the risk allele at
any particular locus. Second, unaffected individuals will
carry multiple risk loci, with the outcomes associated
with any particular risk allele, even high-penetrance al-
leles, depending on the genetic and environmental con-
text and possibly chance [23, 28]. Third, there will be
many different combinations of risk alleles in different
cases. Fourth, individuals with different psychiatric out-
comes will share a proportion of their underlying genetic
risk [48, 50].
Thus, the relationship between psychiatric disorders and
the genome is highly complex and far from a simple one
to one mapping. This is apparent even when we consider
the relatively simple scenario provided by risk CNVs. For
Fig. 2 Illustration of what precision psychiatry might look like. With the increasing use of high-throughput genomic technologies in
clinical genetics (e.g., the 100 K Genomes Project), it is likely that genomics will eventually have a role in psychiatric healthcare.
Quantitative measures of the genetic liability to psychiatric disorders, such as polygenic risk scores, could be combined with additional
clinical variables and psycho-social risk factors to help tailor treatment to the individual at several junctures across the lifespan. We briefly
highlight here four key areas (risk prediction, patient stratification, pharmacogenomic and molecular diagnostics) where precision
psychiatry would directly benefit the management and treatment of patients and provide a general timeline for when they could impact
healthcare across an individual’s lifespan (Fig. 2). Risk prediction: Genetic risk scores could help target early intervention strategies towards
those at greatest risk for developing a major psychiatric disorder. For example, schizophrenia genomic risk scores could be used to help
predict which individuals from phenotypically defined high-risk groups are more likely to develop psychosis. Moreover, individuals who
carry a pathogenic copy number variant could receive additional monitoring and/or screening for psychiatric and/or physical
comorbidities. Patient stratification: Psychiatric disorders are associated with marked clinical variability in disease course and outcome,
both within and across diagnostic categories. Research into biological and environmental exposures associated with this variability will
inform stratification of patients into those that could benefit from tailored programs of treatment. Pharmacogenomics: Pharmacogenomic
variants are known to influence variation in drug response. Precision psychiatry could therefore impact the way drugs are prescribed, by
identifying patients most likely to benefit, predicting the dose required to maximize their therapeutic effects, and identifying patients
who require additional monitoring for adverse side effects. Molecular diagnosis: No individual genetic variant is either necessary or
sufficient to cause psychiatric disorders; however, the identification of rare, highly penetrant risk mutations, such as 22q11.2 deletions, can
help towards providing a diagnostic explanation for the development of a psychiatric disorder. As our knowledge about the penetrance
and phenotypic variability associated with rare risk variants improves, their identification among psychiatric patients will inform both
genetic counseling and the examination of comorbidities
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example, at least eight distinct CNVs are robustly associ-
ated with schizophrenia [6, 32, 48]. However, these display
a combination of incomplete penetrance and variable ex-
pressivity. For instance all schizophrenia risk CNVs are
also associated with ID and many have been associated
with a broad range of other psychiatric, cognitive, motor
and physical disease outcomes [15, 17, 48, 60–62]. The
situation with regard to the large number of alleles of
small effect is likely to be even more complex and, at least
with the majority of currently used psychiatric and behav-
ioral phenotypes, is unlikely to be significantly simplified
by the use of endophenotypes (i.e., measures of pathology
that are heritable, associated with the disorder, and ob-
served in seemingly unaffected individuals) as these appear
to display similarly complex genetic architectures (see
below).
Broadly speaking, there are several headline implica-
tions of these complexities for the potential of genomics
to inform stratification in precision psychiatry. First, we
will have to deal with genomic risk that is spread across
many loci in the genome. Second, genomic profiles alone
are unlikely to delineate circumscribed categories of pa-
tients suitable for specific interventions. Third, genomic
profiling in clinical settings is likely to cut across current
diagnostic categories, psychiatric sub-specialties and
other medical specialties. However, genomics may have
the potential to indicate the probability that an individ-
ual will fall into a particular clinically relevant group, or
for patients carrying rare, high-penetrant mutations (e.g.
CNVs), inform screening for additional comorbidities.
Risk prediction
Common risk alleles are estimated to account for at least
a third of the liability to schizophrenia [29], although
only 6% of this is explained in the largest GWAS pub-
lished to date [4]. Although schizophrenia PRS has been
robustly associated with increased risk for schizophrenia
in real-world clinical settings [63], the predictive ability
of schizophrenia PRS alone is at present too low to be
informative for an individual. However, these approaches
have shown promise in stratifying risk for non-
psychiatric traits that are polygenic. For example, in cor-
onary artery disease (CAD), up to 8% of the population
have been shown to have CAD GRS that confers a level
of risk equivalent to known monogenic rare variants
[64]. Risk prediction will also benefit from combining
GRS with other risk factors, such as age, environmental
exposures and biomarkers; this has been shown in stud-
ies of prostate cancer, where prediction models based on
prostate-specific antigen alone were significantly im-
proved when combined with GRSs and clinical variables
(e.g. age, family history, previous prostate biopsy and
prostate exam) [65].
Researchers have begun to evaluate the clinical utility
of GRS for predicting diagnostic outcomes and response
to treatment in persons meeting research criteria for
psychosis high risk and patients with first-episode psych-
osis. Here, schizophrenia PRS has been shown to be sig-
nificantly elevated in individuals that later developed
schizophrenia compared with those that did not [66, 67],
and there is evidence that patients with lower schizo-
phrenia PRS respond more positively to antipsychotic
treatment [68]. However, the discriminative accuracy of
GRS for predicting outcome and treatment response is
at present too low to be clinically useful [66].
The challenges for mechanistic research
The development of novel, rationally designed treat-
ments will require us to gain new mechanistic insights
from genomic and other data. Psychiatric phenotypes
are complex and difficult to assess objectively and, as we
have seen, most current diagnostic categories are syn-
dromic. The human brain is by several orders of magni-
tude the most complex organ in the body, and it
remains poorly understood and relatively inaccessible to
direct analysis. It follows that, given the resulting low
base of existing mechanistic understanding coupled with
the substantial heritability of psychiatric disorders esti-
mated from genetic epidemiology [69], psychiatry poten-
tially has the most to gain of any branch of medicine
from genomic insights into disease biology and the iden-
tification of novel drug targets. However, the emerging
picture from genomic studies points to a number of key
challenges.
First, GWAS do not always directly identify risk vari-
ants or risk genes, and the large number of loci impli-
cated and low individual effect sizes do not lend
themselves to the canonical functional approaches that
are typically applied to Mendelian disorders. There are
however grounds for optimism given the increasing
availability of sequence-based, functional genomic ap-
proaches that integrate genomic data with functional an-
notations of the genome [70]. These approaches, which
allow functional annotation at genomic scale and the po-
tential ability to identify the casual variants underlying
SNP associations, are increasingly being applied to psy-
chiatric disorders. This work has been supported by ini-
tiatives such as CommonMind and PsychENCODE,
which provide transcriptomic and epigenomic data from
psychiatric cases and controls for the research commu-
nity [71–73]. These resources have been used to gain
novel mechanistic insights into disease pathogenesis
through the development of transcriptome-wide associ-
ation studies (TWAS), which use methods such as ex-
pression quantitative trait loci (eQTL) analysis to refine
risk loci to genes, cells and tissues [74]. Recent schizo-
phrenia TWAS have identified correlations between
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GWAS signals and the expression of 256 genes across
13 different brain regions, with the dorsolateral pre-
frontal cortex (DLPFC) showing the largest number of
significant genes [75]. Another TWAS that focused spe-
cifically on genes expressed in the DLPFC found schizo-
phrenia GWAS loci to be associated with the expression
of 89 genes, with no significant bias for these genes be-
ing preferentially over or under-expressed [76]. Gene-set
analyses have also found TWAS associated genes to be
enriched among FMRP targets [75], as well as genes re-
lated to ‘abnormal central nervous system synaptic
transmission’ and ‘antigen processing and presentation
of peptide antigen via MHC class I’ [76]. Although
TWAS of ASD and BD are currently less powered com-
pared with schizophrenia, recent findings have indicated
that TWAS associated genes are shared across these dis-
orders [77].
GWAS and TWAS have also highlighted putative can-
didates for drug repurposing. For example, schizophre-
nia GWAS studies have implicated genes that are targets
of compounds with approved indications, such as
voltage-gated calcium channels (e.g. CACNA1C,
CACNB2 and CACNA1L); pharmaceutical compounds
that are antagonists or activators for these calcium chan-
nels have been approved for the treatment hypertension,
arrhythmia or epilepsy [78]. Comparisons between drug
induced and disease-associated gene expression profiles
have also identified correlations between known psychi-
atric indications. For example, antipsychotic induced ex-
pression profiles are correlated with GWAS imputed
gene expression profiles for schizophrenia and bipolar
disorder [79]. Correlations between drug induced and
GWAS imputed gene expression profiles could therefore
be used to prioritize candidates for novel drug
repositioning.
However, challenges remain in psychiatry due to the
complexity of the brain compared to other organs and
the possibility that pathogenic mechanisms might oper-
ate over long developmental periods.
Second, recent genomic findings have implications for
human mechanistic studies that attempt to link risk fac-
tors and clinical phenotypes via underlying pathophysi-
ology and mechanisms using so-called endophenotypes
[80], such as measures of cognition, brain structure,
electrophysiology and biochemistry. The assumption
that endophenotypes are in general likely to be less com-
plex genetically than clinical disorders has been ques-
tioned [81]. More importantly, the possibility of
pleiotropy implies the need for caution before conclud-
ing that a particular endophenotype mediates the effect
of risk on clinical phenotypes [46, 82]. For example,
there is strong evidence that the burden of RCVs in
schizophrenia is greatest in patients with comorbid ID,
but RCVs are still enriched in schizophrenia patients
without ID [38]. Therefore, the cognitive impairments
associated with rare variants that confer risk to psychi-
atric disorders do not completely mediate the risk of
psychopathology [46]. The study of endophenotypes
does however offer a promising means by which genetic
risk can be linked to disturbances of brain function [83],
and may help to close the gap between genes and behav-
ior assuming that the results are interpreted with suffi-
cient caution.
Third, the degree to which a very large number of
common variants with low effect sizes confer risk to psy-
chiatric disorders poses challenges for using genomic
discoveries to develop animal and cellular models with
high construct validity (that is, that can adequately
model a psychiatric disorder). The function of individual
genes implicated by GWAS can be explored in animal
models, but it is hard to see how large numbers of hu-
man risk alleles can be modeled with current or emer-
ging technologies, even supposing that a sufficient
number of causal variants can be identified. It is possible
to model rare variants associated with higher risk includ-
ing CNVs and RCVs in rodents [84], thus allowing be-
havioral and network studies as well as molecular
analyses, and the potential of such approaches has been
enhanced by the development of genome engineering
approaches such as CRISPR-based technologies [85]. But
even here, the degree of variable expressivity and plei-
otropy seen in human carriers are grounds for caution
in drawing causal inferences between endophenotypes
and behavior, as is the case in human studies (see above)
[46], and for many psychiatric disorders the number of
individual genes robustly associated with moderate-to-
high-penetrance RCVs or CNV loci has not to date been
great (Table 2).
Many of the same considerations apply to cellular
models, but here there is potential to model human gen-
etic complexity directly in induced pluripotent stem cells
(iPSCs). These can be derived from patients [86] and
also target individuals carrying high-penetrance muta-
tions [87] or on the basis of genomic risk scores or a
combination of the two. Notwithstanding the increasing
interest in brain organoids [88], these approaches are
currently limited in complexity and to early stages of de-
velopment (see below).
The research agenda for translating insights from
genetics to precision psychiatry
Having summarized the advances in psychiatric genom-
ics and the broad challenges facing translation of these
findings, we now consider the priorities for research
aiming to build on these advances to obtain better treat-
ments and to target these effectively. Though we con-
sider them separately, we note that there will need to be
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much cross-talk between the different areas of research
given the limitations associated with each.
Risk prediction
Various methods have been developed to quantify risk,
heritability and genetic correlation from common alleles
[58]. The power of these approaches is increasing as data
from larger GWAS become available, though in the case
of psychiatric disorders, these methods remain under-
powered to be used in population screening. The pre-
dictive utility of such testing will depend on the risk
profile in the group to which the testing is being tar-
geted, as well as the availability of effective preventative
measures that can be targeted to the high-risk groups.
This will require further research, and one area in psych-
iatry that is sure to receive attention is the ability of GRS
to inform management in first-episode psychosis, given
that the outcomes of patients are highly variable follow-
ing treatment. Another important current limitation of
the clinical use of GRS is the lack of ancestral diversity
in GWAS studies, the vast majority of which have been
carried out in individuals with European ancestry [89].
Significantly less heritable variation is explained when
GRSs are applied trans-ethnically [89] and it will require
well-powered GWASs to be undertaken in many diverse
populations to avoid further exacerbation of current glo-
bal health disparities [89].
Heritability estimates for psychiatric disorders from
pedigrees are substantially larger than SNP-based herit-
ability; for example, schizophrenia pedigree and SNP-
based heritability estimates are ~ 80% [90] and 23% [4],
respectively. This difference in heritability is, in part, due
to rare variants that are not tagged on SNP arrays. In-
deed, the importance of accounting for the full fre-
quency distribution of alleles contributing to a polygenic
trait has recently been exemplified in a study of height
and BMI, which used whole genome sequencing (WGS)
to show that heritability estimates from molecular gen-
etic data aligned with those from family and twin studies
when both rare and common alleles were considered
[91].
A number of rare variants have been identified that
confer risk to psychiatric disorders including both
CNVs and RCVs (Table 2 and Fig. 1a), and many
more are likely to be discovered in future large-scale
sequencing studies. As the number of rare variants
associated with psychiatric disorders increases, the use
of WGS has great potential to improve risk predic-
tion/stratification accuracy, as the upper limit of pre-
diction is the heritability; however, increasing the
number of alleles used for out-of-sample prediction
can reduce the expected proportion of variance ex-
plained, and therefore, massive samples are needed
for WGS to enhance prediction accuracy [92].
Identification of CNVs through chromosomal microar-
rays (CMA) is increasingly becoming part of routine
clinical testing for ID, DD, and ASD [93] and is cur-
rently considered the first-tier test for undiagnosed
NDDs. However, there is a strong case for exome se-
quencing to replace CMA as a first-tier test, given evi-
dence that it provides a higher diagnostic yield for
NDDs (36%, compared with 15–20% from CMA) [94].
With the continued reduction in the cost of sequencing,
it also seems highly likely that whole genome sequencing
will increasingly be applied in these conditions to detect
pathogenic RCVs. There have also been calls for extend-
ing CMA testing to schizophrenia [95]. Currently, such
tests may offer patients and families a degree of diagnos-
tic explanation and also point to the need for genetic
counseling as well as indicating increased risk for associ-
ated physical comorbidities. However, these tests do not
currently offer much in the way of predictive informa-
tion about psychiatric or behavioral outcomes or infor-
mation of direct therapeutic relevance. It will be
challenging to acquire informative data in these areas
given the high degree of pleiotropy and the rarity of
many of the pathogenic mutations, and this will require
coordinated data sharing across many centers along the
lines of the DECIPHER database for DD in the UK [96].
Identifying novel strata for precision medicine
The aim of precision medicine is to tailor healthcare, in-
cluding prevention and decisions on treatment and care
pathways, more effectively to the needs of individual pa-
tients. For this to succeed in psychiatry, it is clear that
we need new ways of characterizing patients or groups
of patients according to attributes that will allow health-
care to be targeted more effectively. There is now a
pressing need to understand how and to what extent
genomic variation underlies the variability in symptoms,
treatment response, course, and outcome seen in psychi-
atric disorders, and to determine whether genomic data
can contribute to the development of clinically useful
strata. For the reasons of polygenicity and pleiotropy
outlined above, it seems unlikely that genomics alone
alongside current diagnostic categories will satisfy this
criterion, though this is a matter for empirical enquiry.
Rather, it seems likely that the potential of genomic pro-
filing in precision psychiatry to provide clinically action-
able information such as the likelihood of response to a
particular drug or other intervention will be its use in
concert with other clinical features such as specific
symptom profiles, developmental profiles, cognitive, im-
aging, and other biomarkers.
This is a crucial area if we are to translate genomic
discovery into patient benefit, but its potential will only
be realized if we develop sufficiently large-scale datasets
in which genomic data can be analyzed together with
Rees and Owen Genome Medicine           (2020) 12:43 Page 10 of 16
informative phenotypic data. Many of the samples used
for psychiatric GWAS have not been phenotyped at
depth, and when they have, divergent methods have
been employed across sites. There is a need for a major
effort here to collate and collect large richly phenotyped
samples, to coordinate phenotyping across sites and
make the data available to other researchers. Current
and emerging population studies and cohorts can play a
role in this but typically mental health data are scanty in
such samples and for various reasons severe psychiatric
disorders such as schizophrenia and childhood NDDs
tend to be underrepresented in such studies. There is
also huge potential to leverage advances in “Big Data”
approaches including access to electronic health records
and digital phenotyping [97].
A major challenge facing precision psychiatry is the
huge variability in disease course and outcome seen
within our currently imprecise diagnostic categories.
It is unclear to what extent this reflects diagnostic
heterogeneity, pharmacogenetic factors, environmental
exposures, or a host of potential factors influencing
individual differences impacting behavior. What is
clear is that if we are to develop effective precision
psychiatry, we need to identify the factors that predict
disease course and outcome and this will require suit-
ably powered datasets that capture clinical data over
extended time periods. It is hard to see how this can
be achieved without access to routinely collected clin-
ical data.
Access to such data is important for a second reason.
The great majority of genomic studies aim to identify
genetic variants associated with the occurrence of dis-
ease. Such variants may well have utility in informing
disease prevention, but it may be the case that genes in-
volved in disease progression might be of greater rele-
vance to the development of therapeutic strategies [98].
There is thus a need for more genomic studies of dis-
ease course and outcome (Fig. 2). These have been
scarce due in part to difficulties in defining progression
variables, especially in psychiatry, and there are potential
biases that need to be taken into account [98]. However,
through ongoing efforts to link large genetic datasets to
electronic health records, thus providing longitudinal
phenotypic data, we expect to see progress in this area
over the coming years.
Another area in which we can expect progress in the
application of genomics to precision psychiatry is in
pharmacogenomics aiming to identify patient groups
that are more or less likely to respond to particular
drugs or to develop important adverse effects (Fig. 2).
To date, most interest has been focused upon pharmaco-
genetic evidence implicating the genes encoding known
drug metabolizing enzymes, and the HLA system in de-
termining risk to certain adverse effects [99] and, for
example, promising findings have recently emerged in
relation to risperidone dosage and drug metabolism
[100, 101]. However, genomics offers the prospect of
undertaking wider, unbiased, searches. Here, the press-
ing need is for sufficiently powered samples containing
reliable and valid data on drug response and adverse ef-
fects. There are however promising signs of progress.
For example, there is emerging evidence that genetic
architecture of susceptibility to schizophrenia may be
distinct from that of treatment outcomes [102], and pro-
gress is being made in identifying common genetic vari-
ants that have large effects on the metabolism of
clozapine and its metabolites, opening the way for clin-
ical studies assessing the use of pharmacogenomics in
the clinical management of patients with treatment-
resistant schizophrenia [101]. In addition, a recent gen-
omic study has indicated that the high rates of neutro-
penia seen in African ancestry individuals taking
clozapine is due to the high frequency of the Duffy-null
genotype (Duffy is a red blood cell glycoprotein) in these
individuals rather than to the toxic effects of clozapine,
which require discontinuation of treatment [103]. The
neutropenia associated with the Duffy-null genotype is
benign, and these findings suggest that simple genotyp-
ing at the locus may allow a rapid diagnosis of “benign
ethnic neutropenia” and ensure that many individuals of
African ancestry who require clozapine treatment are
able to continue treatment despite the presence of
neutropenia.
Advances in genomic medicine, in particular for disor-
ders where clinically actionable gene-drug associations
exist, have prompted the development of online public
databases that summarize published pharmacogenomic
findings. For example, PharmGKB [104] provides a
manually curated knowledgebase for the research com-
munity about genetic variants that influence differences
in drug efficacy, dose, and toxicity/adverse drug reac-
tions. The disorders and phenotypes in PharmGKB are
comprehensive, and over 150 variant-drug associations
are available for schizophrenia; however, many of these
associations are derived from small and/or candidate
gene studies and thus would not meet accepted stan-
dards for robust evidence. An advantage of PharmGKB
is that for each drug-variant association, a level of evi-
dence score is provided based on statistical evidence and
reproducibility, although these “evidence levels” may not
always align with those of the genomics research com-
munity. The PharmGKB interface allows for users to fil-
ter drug-variant associations for important evidence
criteria, such as sample size and p values, as well as pro-
viding links to primary publications, thus allowing users
to make their own assessment of the evidence for a
drug-variant association. For example, the largest drug-
variant study for schizophrenia in PharmGKB (N
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samples = 8133) reports a common allele on chromo-
some 12 (rs149104283) associated with clozapine-
induced neutropenia (odds ratio (OR) = 4.32, P = 1.79 ×
10− 8) [105]. In summary, databases such as PharmGKB
provide a useful resource for the research community,
but the associations reported should be treated with cau-
tion and users should conduct their own assessment of
the level of evidence presented for drug-variant
associations.
Population studies
One of the corollaries of polygenicity is that genetic risk
is spread across the population. This provides an im-
portant opportunity to undertake research into the im-
pact of genetic risk in cohorts and epidemiological
samples taken from the general population. To the ex-
tent that this may involve individuals without the disease
in question, this mitigates the risk of reverse causation
and drug effects, though other sources of confounding
may not be excluded [106]. Samples such as the UK Bio-
bank, the ALSPAC birth cohort, the ABCD study, and
those available to the Enigma neuroimaging consortium
are currently being explored in relation to genetic risk
for psychiatric disorders [17, 107–111]. These studies
can help identify endophenotypic markers of risk such
as brain structure [112, 113] and cognitive impairment
[62, 114] and developmental antecedents [115]. Popula-
tion studies of this sort, especially when combined with
the functional genomic approaches described below,
offer windows into understanding disease risk mecha-
nisms and how they manifest over the lifespan. Such in-
sights when applied to clinical populations are likely to
also impact on stratification.
Understanding disease mechanisms
As we have seen, the complex genetic architecture of
psychiatric disorders poses many challenges for attempts
to translate genomics into mechanistic insights. Many of
these challenges and potential solutions have recently
been reviewed in detail by others [71, 116] and readers
are referred to these articles for detailed treatments of
the issues, and the methods and resources available.
Broadly speaking, we can define the priority areas of
research as follows. First, since most common genetic
variation contributing to psychiatric disorders lies out-
side protein-coding regions, a major effort will be re-
quired to understand which genes are impacted by risk
variants and the direction of effect. This will require the
functional annotation of regulatory regions at a genome-
wide scale. Moreover, the size of sequencing studies will
increase significantly over the coming years, which will
provide powerful approaches for identifying specific tar-
get genes associated with rare coding variants. Second,
genes do not operate in isolation but rather as parts of
networks or pathways, and understanding how polygenic
inheritance impacts on such networks and identifying
whether risk genes converge on sets of common net-
works is another major effort that is underway. Third,
there is a need to drill down into the question of
whether genetic risk operates in specific neurons or
groups of neurons and to address the issue of whether
risk impacts on the brain at particular points in develop-
ment. Work across these areas is intensive and is devel-
oping rapidly [71, 116], and despite the complexity,
there have been some promising findings indicating con-
vergence onto genes implicated in neuronal communica-
tion, especially synaptic genes, and regulation of gene
expression, including transcription factors and chroma-
tin modification gene sets [5, 14, 31, 53, 117]. Finally,
while we can expect many findings to be published ad-
dressing these issues in the next 5 years, it is hard to
avoid the conclusion that their applicability to precision
psychiatry will be limited if they are exclusively anchored
to existing syndromic diagnoses. Ultimately, if we are to
understand how putative disease mechanisms impact on
outcome or response to treatments, we will need to take
a more diagnostically agnostic approach and begin to re-
late such mechanisms to sufficiently fine-grained pheno-
typic data in most of the large datasets subjected to
genomic analysis.
Model systems
The complex and pleiotropic genetic architecture of psy-
chiatric disorders pose great challenges for work in
model systems as we have seen. There is scope to con-
tinue developing animal models based upon high-
penetrance RCVs or CNVs. However, given the poly-
genic basis of psychiatric disorders, it seems increasingly
unlikely that simple pathways from gene to biology to
behavior will be found. It may be possible to use inter-
ventional methods such as optogenetics [118] to estab-
lish causative pathways between genes and behavior.
There will also be a need to model developmental effects
and the variability of phenotypic outcomes (genetic
background, environmental exposures). There are also
well-articulated concerns about the face validity of ani-
mal models, particularly of behavior, in psychiatric re-
search [119].
Given advances in stem cell technology it seems
likely that there will be a growth of studies using cel-
lular models, which can accommodate genetic com-
plexity by taking cells from patients or high-risk
individuals and be subject to experimental manipula-
tion and drug testing. iPSC models have been applied
to a range of psychiatric disorders including schizophre-
nia, bipolar disorder, and Rett syndrome [120]. However,
there are intrinsic caveats associated with these ap-
proaches that include artifactual heterogeneity, due to
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factors such as somatic mosaicism in donor cells and de
novo mutations occurring during cell reprogramming, loss
of epigenetic modifications, and the developmental imma-
turity of iPSC-derived neurons [121]. Other issues that
will need to be addressed are the question of which cell
types should be studied in modeling particular disorders
and this may be informed by functional genomic studies
linking human genomic data with single-cell RNA sequen-
cing datasets [14, 57].
There is also burgeoning interest in the potential of
brain organoids to provide better models of brain devel-
opment and brain diseases than 2D iPSC models [88].
This is a rapidly developing field that is still in the early
phases of development and consequently a number of
challenges remain to be addressed [88]. The limitations
intrinsic to simpler iPSC models still apply but orga-
noids potentially provide an approach whereby the ef-
fects of genetic risk on complex cellular interactions can
be modeled in human tissue. Since organoids mature
slowly, these approaches may be best applied to model-
ing disease phenotypes that manifest at early stages of
development and encouraging findings have been re-
ported in severe neurodevelopmental disorders such as
microcephaly, lissencephaly, and Timothy syndrome
[88]. Whether they will be informative for disorders
which manifest later in life remains to be seen, though
encouraging findings have been reported in Alzheimer
disease [122].
Conclusions
The many genomic advances that have been made over
the past 20 years have taken us from a state of almost
total ignorance as to the biological underpinnings of psy-
chiatric disorders to an appreciation of the underlying
complexity, the identification of a large number of risk
factors and loci, and the realization that genetic risk
maps poorly onto the diagnostic categories that we use
in the clinic. In spite of this success and the multitude of
new findings, there is more genetics research needed.
Much of the heritability of psychiatric disorders remains
unexplained by common SNPs and rare mutations, and
there is emerging evidence implicating rare missense
and rare non-coding variants that will require whole
genome sequencing in large samples [14, 39, 91, 123].
The power and utility of genomic approaches to enable
risk prediction and stratification will increase as genomic
data accumulate, and further benefit will accrue from ef-
forts to integrate genomic data with more fine-grained
and longitudinal phenotypic data. There is potential for
current genomic findings to have an immediate impact
on psychiatry; for example, testing rare pathogenic
CNVs in patients would inform screening for comorbidi-
ties, and genotyping the Duffy-null allele in patients of
African ancestry would inform clozapine treatment. The
highly polygenic nature of psychiatric disorders poses
challenges for conventional approaches in moving from
genes to biology. The hope is that combining genetics,
functional genomics and single-cell RNA sequencing will
identify convergence onto specific systems, cell types,
circuits, developmental stages, etc. There is much to do
here using in vivo, in vitro, and increasingly, in silico ap-
proaches. As large-scale omics studies continue to eluci-
date the molecular basis of psychiatric disorders, it is
likely that integrating different types of omics data pro-
duced from the same samples will enhance approaches
to define biologically meaningful subtypes of patients.
Identifying patient subtypes that differ with regard to
disease progression, clinical outcomes, and treatment re-
sponse has great potential to enable targeted treatment
and improve clinical trials, as has been clearly demon-
strated in the field of oncology [124, 125].
While there are certainly challenges to overcome, gen-
omics has built an empirical platform upon which
psychiatry can now progress towards better understand-
ing of disease mechanisms, better treatments, and to
better ways of targeting treatments to the patients most
likely to benefit, thus paving the way for precision
psychiatry.
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